Literature DB >> 21218563

The moderating effect of the APOE [small element of] 4 allele on the relationship between hippocampal volume and cognitive decline in older depressed patients.

Natalie Sachs-Erisson1, Kathryn Sawyer, Elizabeth Corsentino, Nicole Collins, David C Steffens.   

Abstract

OBJECTIVE: the apolipoprotein E epsilon-4 (APOE [small element of] 4) allele and depression are independently associated with increased risk for cognitive decline (CD). The authors have reported that depressed elders with an APOE [small element of]4 allele had greater CD compared with depressed elders without the allele. Depression affects the hippocampus, and reduced hippocampal volume has been associated with CD. This study sought to examine in depressed patients the relationships between hippocampal volume, the APOE [small element of] 4 allele, and their interaction on CD. Analyses were performed to examine the influence of baseline hippocampal volume, the APOE [small element of] 4 allele, and their interactions on change in cognitive functioning overtime.
DESIGN: secondary data analysis using linear regression analyses.
SETTING: clinical Research Center for the Study of Depression in Later Life conducted at Duke University. PARTICIPANTS: depressed older patients (N = 61) followed up for 4 years. MEASURES: At baseline, cognitive functioning (assessed by the Mini-Mental State Examination), left and right hippocampal volume (assessed by magnetic resonance imaging), and APOE genotype were obtained. At 4-year follow-up, cognitive functioning was reassessed.
RESULTS: the APOE [small element of] 4 allele and left hippocampal volume, but not right hippocampal volume, were independently associated with CD. Importantly, the authors found the APOE [small element of]4 allele to moderate the effects of left hippocampal volume on CD. The APOE [small element of]4 allele seemed to have little effect among those with larger left hippocampal volumes, whereas the allele influenced CD among those with smaller hippocampal volumes.
CONCLUSION: future studies of cognitive impairment and decline should examine both individual and conjoint effects of putative risk factors. 2011 American Association for Geriatric Psychiatry

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21218563      PMCID: PMC3057467          DOI: 10.1097/jgp.0b013e3181f61ae8

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  37 in total

1.  The temporal relationship between depressive symptoms and dementia: a community-based prospective study.

Authors:  P Chen; M Ganguli; B H Mulsant; S T DeKosky
Journal:  Arch Gen Psychiatry       Date:  1999-03

2.  Depressive symptomatology and incident cognitive decline in an elderly community sample.

Authors:  S S Bassuk; L F Berkman; D Wypij
Journal:  Arch Gen Psychiatry       Date:  1998-12

3.  Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression.

Authors:  Y I Sheline; M Sanghavi; M A Mintun; M H Gado
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

4.  Vasopressin and corticotropin-releasing hormone gene responses to novel stress in rats adapted to repeated restraint.

Authors:  X M Ma; S L Lightman; G Aguilera
Journal:  Endocrinology       Date:  1999-08       Impact factor: 4.736

5.  Methodology and preliminary results from the neurocognitive outcomes of depression in the elderly study.

Authors:  David C Steffens; Kathleen A Welsh-Bohmer; James R Burke; Brenda L Plassman; John L Beyer; Kenneth R Gersing; Guy G Potter
Journal:  J Geriatr Psychiatry Neurol       Date:  2004-12       Impact factor: 2.680

6.  Executive deficits in elderly patients with major unipolar depression.

Authors:  Sophie Baudic; Catherine Tzortzis; Gianfranco Dalla Barba; Latchezar Traykov
Journal:  J Geriatr Psychiatry Neurol       Date:  2004-12       Impact factor: 2.680

7.  Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation.

Authors:  T G Ohm; M Kirca; J Bohl; H Scharnagl; W Gross; W März
Journal:  Neuroscience       Date:  1995-06       Impact factor: 3.590

8.  Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study.

Authors:  P J Shah; K P Ebmeier; M F Glabus; G M Goodwin
Journal:  Br J Psychiatry       Date:  1998-06       Impact factor: 9.319

9.  Longitudinal analysis of the association between depressive symptomatology and cognitive deterioration.

Authors:  C Dufouil; R Fuhrer; J F Dartigues; A Alpérovitch
Journal:  Am J Epidemiol       Date:  1996-10-01       Impact factor: 4.897

10.  Misdiagnosing delirium as depression in medically ill elderly patients.

Authors:  K R Farrell; L Ganzini
Journal:  Arch Intern Med       Date:  1995 Dec 11-25
View more
  4 in total

1.  Neuroimaging in geriatric psychiatry: integrative research as the next frontier.

Authors:  Olusola Ajilore; Gwenn S Smith
Journal:  Am J Geriatr Psychiatry       Date:  2011-01       Impact factor: 4.105

2.  Divergent Roles of Vascular Burden and Neurodegeneration in the Cognitive Decline of Geriatric Depression Patients and Mild Cognitive Impairment Patients.

Authors:  Qing Ye; Fan Su; Liang Gong; Hao Shu; Wenxiang Liao; Chunming Xie; Hong Zhou; Zhijun Zhang; Feng Bai
Journal:  Front Aging Neurosci       Date:  2017-09-01       Impact factor: 5.750

3.  Physical activity, cognitive function, and brain health: what is the role of exercise training in the prevention of dementia?

Authors:  Sara M Gregory; Beth Parker; Paul D Thompson
Journal:  Brain Sci       Date:  2012-11-29

4.  Apolipoprotein E genotype does not moderate the associations of depressive symptoms, neuroticism and allostatic load with cognitive ability and cognitive aging in the Lothian Birth Cohort 1936.

Authors:  Zander Crook; Tom Booth; Simon R Cox; Janie Corley; Dominika Dykiert; Paul Redmond; Alison Pattie; Adele M Taylor; Sarah E Harris; John M Starr; Ian J Deary
Journal:  PLoS One       Date:  2018-02-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.